Follow-up of a French national cohort of melanoma stage IV and unresectable stage III patients, MelBase.
Clara Allayous(Inserm), Célèste Lebbé(Inserm), A. Kowal(Université Paris Cité), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), S. Dalac(CHU Dijon Bourgogne), Jean‐Philippe Arnault(Centre Hospitalier Universitaire Amiens-Picardie), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), A. Dupuy(Université de Rennes), E. Maubec(Inserm), F. Aubin(Centre Hospitalier Universitaire de Besançon), L. Verneuil(Centre Hospitalier Sainte-Anne), Philippe Bahadoran, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Raphaël Porcher(Hotel Dieu Hospital), Stéphane Dalle(Hospices Civils de Lyon), Laurent Mortier, Brigitte Dréno(Nantes Université), Pierre‐Emmanuel Stoebner(Centre Hospitalier Universitaire de Nîmes), M. Beylot‐Barry(Université de Bordeaux)
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k